Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 1/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 5/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.33 |
| ▸ | CDK4 | P11802 | 3/20 | 0.33 |
| ▸ | CCND1 | P24385 | 3/20 | 0.33 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.33 |
| ▸ | CDK2 | P24941 | 2/20 | 0.33 |
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
| ▸ | PRKCI | P41743 | 1/20 | 0.31 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11005480 | 0.79 | CMA1 (0.48) | CMA1NR1H2NR1H3CDK4CCND1 | |
| SCHEMBL1691863 | 0.79 | CYP19A1 (0.36) | RIPK1CDK4CCND1 | |
| SCHEMBL3279187 | 0.78 | CMA1 (0.44) | CMA1NR1H2NR1H3CDK4CCND1 | |
| SCHEMBL689243 | 0.78 | CMA1 (0.47) | CMA1NR1H2NR1H3CDK4CCND1 | |
| SCHEMBL3132206 | 0.78 | CMA1 (0.44) | CMA1NR1H2NR1H3CDK4CCND1 | |
| Hydrochloric Acid SCHEMBL26107888 | 0.76 | CMA1 (0.43) | CMA1NR1H2NR1H3CDK4CCND1 | |
| SCHEMBL10264882 | 0.76 | CMA1 (0.43) | CMA1NR1H2NR1H3CDK4CCND1 | |
| SCHEMBL1251799 | 0.75 | IFNAR1 (0.45) | CMA1NR1H2NR1H3CDK4CCND1 | |
| SCHEMBL31370531 | 0.75 | CMA1 (0.42) | CMA1CDK4CCND1CCNE2CCNE1 | |
| SCHEMBL3143493 | 0.75 | CMA1 (0.45) | CMA1NR1H2NR1H3CDK4CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150353495-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | ALEXION PHARMACEUTICALS, INC. | 2015-12-10 | — | — | US | disclosed |
| US-9102625-B2 | Nicotinamides as JAK kinase modulators | PORTOLA PHARMACEUTICALS, INC. (US) | 2015-08-11 | — | — | US | disclosed |
| US-20120108566-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353495-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | JAK2, JAK1, NADK | CMA1 2625/4885RIPK1 182/4885NR1H2 3805/4885 |
| US-20120108566-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | JAK2, JAK1, NADK | CMA1 2625/4885RIPK1 182/4885NR1H2 3805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.